Down-regulation of transforming growth factor-β and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs

Journal of Neuro-Oncology

Volumn 39, Issue 3, 1998, Pages 229-236

  Naganuma, Hirofumi ^a   Sasaki, Atsushi ^a   Satoh, Eiji ^a   Nagasaka, Mitsuyasu ^a   Nakano, Shin ^a   Isoe, Shiro ^a   Nukui, Hideaki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Anticancer; Drug; Interferon ; Interleukin 10; Interleukin 1 ; Malignant glioma; Transforming growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CYTOKINE; ETOPOSIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CELL SECRETION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PROTEIN EXPRESSION;

EID: 0031759945     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1005902120612     Document Type: Article

References (52)

1. Howard M, O'Garra A: Biological properties of interleukin-10. Immunol Today 13: 198-200, 1992
2. Ding L, Shcvach EM: IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 148: 3133-3139, 1992
3. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 137: 3855-3860, 1986
4. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: 1986. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037-1050, 1986
5. Espevik T, Figari IS, Ranges GE, Palladino MA: Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β2, and recombinant human TGF-β1. J Immunol 140: 2312-2316, 1988
6. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA: Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med 166: 571-576, 1987
7. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-3920, 1986
8. Ranges GE, Figari IS, Espevik T, Palladino Jr MA: Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 166: 991-998, 1987
9. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71: 211-217, 1989
10. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN: Effect of the expression of transforming growth factor-β2 in primary human glioblastoma on immunosuppression and loss of immune surveillance. J Neurosurg 76: 799-804, 1992
11. Carlino JA, Singh N, Avis PD: Preliminary phenotypic characterization of white blood cell changes induced in mice by administration of transforming growth factor-β1. Ann NY Acad Sci 628: 59-62, 1991
12. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-β: biological function and chemical structure. Science 233: 532-534, 1986
13. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B: Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 105:1039-1045, 1987
14. Cheifetz S, Weatherbee JA, Tsang MLS, Anderson JK, Mole JE, Lucas R, Massague J: The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell 48: 409-415, 1987
15. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AD, Sporn MB, Goeddel DV: Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 316: 701-705, 1985
16. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, Moses HL, Chen EY: A new type of transforming growth factor-β, TGF-β3. EMBO J 7: 3737-3743, 1988
17. Madisen L, Webb NR, Rose TM, Marquardt H, Ikeda T, Twardzik D, Seyedin S, Purchio AF: Transforming growth factor-β2: cDNA cloning and sequence analysis. DNA 7: 1-8, 1988
18. Constam DB, Philipp J, Malipiero UV, Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-β1, -β2, and -β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148: 1404-1410, 1992
19. Naganuma H, Sasaki A, Satoh E, Sakihama T, Tasaka K, Nukui H: Improved bioassay for the detection of transforming growth factor-β1 and β2 in malignant gliomas. Neurol Med Chir (Tokyo) 34: 143-149, 1994
20. Sasaki A, Naganuma H, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H: Secretion of transforming growth factor-β1 and β2 by malignant glioma cells. Neurol Med Chir (Tokyo) 35: 423-430, 1995
21. Wrann M, Bodmer S, de Martin R, Spiel C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 6: 1633-1636, 1987
22. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Tasaka K, Nukui H: Inhibition of tumor necrosis factor-α and -β secretion by lymphokine activated killer cells by transforming growth factor-β. Jpn J Cancer Res 85: 952-957, 1994
23. Danielpour D, Kim KY, Winokur TS, Sporn MB: Differential regulation of the expression of transforming growth factor-βs 1 and 2 by retinoic acid, epidermal growth factor, and dexamethasone in NRK-49F and A549 cells. J Cell Physiol 148: 235-244, 1991
24. Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE: Accessory cell signals involved in T-cell activation. Immunol Rev 117: 5-66, 1990
25. van Scvcntcr GA, Shimizu Y, Horgan KJ, Shaw S: The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144: 4579-4586, 1990
26. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med 173: 721-730, 1991
27. Azuma M, Cayabyab M, Phillips JH, Lanier LL: Requirement for CD28-dependent T cell-mediated cytotoxicity. J Immunol 150: 2091-2101, 1993
28. Satoh E, Naganuma H, Sasaki A, Nagasaka M, Tasaka K, Nukui H: Effect of anticancer drugs on transforming growth factor-β secretion by malignant glioma cells. Neuroimmunol Res 7: 230-233, 1994 (in Japanese)
29. Naganuma H, Sasaki A, Nukui H, Tasaka K: Antiproliferative cytokines secreted by lymphokine-activated killer cells stimulated with tumor cells. J Neurosurg 77: 411-416, 1992
30. Ding L, Linsley PS, Huang L, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151: 1224-1234, 1993
31. Ranheim EA, Kipps TJ: Tumor necrosis factor-α facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol 161: 226-235, 1995
32. Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW: IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol 152: 5723-5733, 1995
33. Chang CII, Furue M, Tamaki K: B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-γ or by interleukin-10. Eur J Immunol 25: 394-398, 1995
34. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Nukui H: Modulation of transforming growth factor β secretion from malignant glioma cells by interleukin-1β. Neurol Med Chir (Tokyo) 36: 145-150, 1996
35. Danforth DN Jr, Sgagia MK: Interleukin-1α and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 53: 1538-1545, 1993
36. Phan SH, Gharaee-Kermani M, McGarry B, Kunkel SL, Wolber FW: Regulation of rat pulmonary artery endothelial cell transforming growth factor-β production by IL-1β and tumor necrosis factor-α. J Immunol 149: 103-106, 1992
37. Huettner C, Paulus W, Roggendorf W: Messenger RNA expression of the immuno-suppressive cytokine IL-10 in human gliomas. Am J Pathol 146: 317-322, 1995
38. Nitta T, Hishii M, Sato K, Okumura K: Selective expression of interleukin-10 gene within glioblastoma multiforme. Rrain Res 649: 122-128, 1994
39. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55: 96-101, 1993
40. Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Doughcrty GJ, McBride WH: Down-regulation of murine fibrosarcoma transforming growth factor-β1 expression by interleukin 7. J Nat Cancer Inst 87: 593-597, 1995
41. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD: Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1. Cancer Res 52: 1386-1392, 1992
42. Jin B, Scott JL, Vadas MA, Burns GF: TGF-β down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunol 66: 570-576, 1989
43. Satoh E, Naganuma H, Sasaki A, Nagasaka M, Tasaka J, Ogata H, Uchiyama S, Nukui H: Effect of irradiation on transforming growth factor-β secretion by malignant glioma cells. J Neuro-Oncol 33: 195-200, 1977
44. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R: Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371-2376, 1994
45. Salazar-Onfray F, Petersson M, Franksson L, Matsuda M, Blankenstein T, Karre K, Kiessling R: IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 154: 6291-6298, 1995
46. Sawamura Y, Abe H, Aida T, Hosokawa M, Kobayashi H: Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 69: 745-750, 1988
47. Koulova L, Clark EA, Shu G, Dupont B: The CD28 ligand B7/BB-1 provides costimulatory signal for alloactivation of CD4 + T cells. J Exp Med 173: 759-762, 1991
48. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadlar LM: B-cell surface B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin-2. Proc Natl Acad Sci USA 88: 6575-6579, 1991
49. Jenkins MK, Taylor PS, Norton SD, Urdhl KB: CD 28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 147: 2461-2466, 1991
50. Schwarz RH: A cell culture model for T lymphocyte clonal anergy. Science 248: 1349-1356, 1990
51. Shahinian A, Pfeffer K, Lee KP: Differential T cell costimulatory requirement in CD28-deficient mice. Science 261: 609-612, 1993
52. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS: 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102, 1992